Rep. Thomas H. Kean, Jr. Sells Off Shares of Stryker Corporation (NYSE:SYK)

Key Points

• Rep. Thomas H. Kean, Jr. disclosed a sale of Stryker Corporation shares valued between $15,001 and $50,000 on September 12th, 2025.
• Stryker announced a quarterly dividend of $0.84 per share, with an annualized yield of 0.9%, payable on October 31st.
• The company reported a quarterly revenue of $6.02 billion for the last quarter, exceeding analysts' expectations and representing an 11.1% increase from the previous year.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Corporation NYSE: SYK. In a filing disclosed on October 14th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on September 12th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intercontinental Exchange NYSE: ICE on 9/25/2025.
• Sold $1,001 - $15,000 in shares of Oracle NYSE: ORCL on 9/15/2025.
• Sold $15,001 - $50,000 in shares of Markel Group NYSE: MKL on 9/12/2025.
• Sold $15,001 - $50,000 in shares of Oracle NYSE: ORCL on 9/12/2025.
• Purchased $1,001 - $15,000 in shares of Danaher NYSE: DHR on 9/3/2025.
• Purchased $1,001 - $15,000 in shares of Franco-Nevada NYSE: FNV on 9/3/2025.
• Sold $15,001 - $50,000 in shares of Franklin Resources NYSE: BEN on 9/3/2025.
• Sold $1,001 - $15,000 in shares of Stryker NYSE: SYK on 8/25/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 8/25/2025.
• Purchased $1,001 - $15,000 in shares of Canadian Pacific Kansas City NYSE: CP on 8/22/2025.

Stryker Trading Down 0.2%

NYSE:SYK opened at $369.05 on Friday. The company has a fifty day moving average of $379.46 and a 200 day moving average of $378.76. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $141.09 billion, a P/E ratio of 48.88, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio is currently 44.50%.

Hedge Funds Weigh In On Stryker

Several institutional investors and hedge funds have recently modified their holdings of SYK. Norges Bank bought a new position in shares of Stryker during the second quarter valued at $1,882,173,000. Alliancebernstein L.P. increased its stake in Stryker by 307.6% during the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company's stock valued at $2,214,146,000 after purchasing an additional 4,223,366 shares in the last quarter. Nuveen LLC bought a new stake in Stryker during the 1st quarter valued at about $558,075,000. Corient Private Wealth LLC increased its position in shares of Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock valued at $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company's stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on SYK shares. Redburn Partners set a $420.00 price target on Stryker in a research report on Thursday, September 18th. Evercore ISI decreased their target price on Stryker from $418.00 to $410.00 and set an "outperform" rating for the company in a report on Tuesday, October 7th. Rothschild Redb upgraded Stryker to a "hold" rating in a report on Thursday, September 18th. UBS Group set a $408.00 price objective on shares of Stryker in a report on Monday. Finally, Needham & Company LLC upped their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $431.76.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.